{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:12:24Z","timestamp":1790194344346,"version":"4.1.0"},"reference-count":46,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2013,12,5]]},"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To examine contemporary survival patterns in the general population of patients diagnosed with chronic myeloid leukaemia (CML), and to identify patient groups with less than optimal outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective population-based cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The UK's Haematological Malignancy Research Network (catchment population 3.6 million, with &gt;2000 new haematological malignancies diagnosed annually).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All patients newly diagnosed with CML, from September 2004 to August 2011 and followed up to 31 March 2013.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measure<\/jats:title>\n                    <jats:p>Incidence and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>With a median diagnostic age of 59\u2005years, the CML age standardised (European) incidence was 0.9\/100\u2005000 (95% CIs 0.8 to 0.9), 5-year overall survival was 78.9% (72.3 to 84.0) and 5-year relative survival 88.6% (81.0 to 93.3). The efficacy of treatment across all ages was clearly demonstrated; the relative survival curves for those under 60 and over 60\u2005years being closely aligned. Survival findings were similar for men and women, but varied with deprivation; the age and sex adjusted HR being 3.43 (1.89 to 6.22) for deprivation categories 4\u20135 (less affluent) versus 1\u20133 (more affluent). None of these differences were attributable to the biological features of the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When therapy is freely provided, population-based survival for CML is similar to that reported in clinical trials, and age loses its prognostic significance. However, although most of the patients with CML now experience close to normal lifespans, those living in more deprived areas tend to have poorer outcomes, despite receiving the same clinical care. A significant improvement in overall population outcomes could be achieved if these socioeconomic differences, which may reflect the treatment compliance, could be eliminated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2013-004266","type":"journal-article","created":{"date-parts":[[2014,1,16]],"date-time":"2014-01-16T20:49:20Z","timestamp":1389905360000},"page":"e004266","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":47,"title":["Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort"],"prefix":"10.1136","volume":"4","author":[{"given":"A G","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Painter","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D A","family":"Howell","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Evans","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, St James University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Smith","sequence":"additional","affiliation":[{"name":"St. James's Institute of Oncology, St James's University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Patmore","sequence":"additional","affiliation":[{"name":"Queens Centre for Oncology, Castle Hill Hospital, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Jack","sequence":"additional","affiliation":[{"name":"Haematological Malignancy Diagnostic Service, St James University Hospital, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Roman","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,1,15]]},"reference":[{"key":"2025121411274576000_4.1.e004266.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"2025121411274576000_4.1.e004266.2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2012.1.105"},{"issue":"(Suppl 3)","key":"2025121411274576000_4.1.e004266.3","first-page":"S1","article-title":"Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure","volume":"10","author":"Cortes","year":"2012","journal-title":"J Natl Compr Cancer Netw"},{"key":"2025121411274576000_4.1.e004266.4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23282"},{"key":"2025121411274576000_4.1.e004266.5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11899-012-0151-0","article-title":"Management of the new patient with CML in chronic phase","volume":"8","author":"Marin","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"2025121411274576000_4.1.e004266.6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090381"},{"key":"2025121411274576000_4.1.e004266.7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21942"},{"key":"2025121411274576000_4.1.e004266.8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.245"},{"key":"2025121411274576000_4.1.e004266.9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0393"},{"key":"2025121411274576000_4.1.e004266.10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.225"},{"key":"2025121411274576000_4.1.e004266.11","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-70"},{"key":"2025121411274576000_4.1.e004266.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"2025121411274576000_4.1.e004266.13","unstructured":"Howlader N Noone AM Krapcho M . SEER Cancer Statistics Review, 1975\u20132010, National Cancer Institute. Bethesda. http\/\/seer.cancer.gov\/csr\/1975_2010\/, based Novemb 2012 SEER data submission, posted to SEER web site, April 2013 2013."},{"key":"2025121411274576000_4.1.e004266.14","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.745525"},{"key":"2025121411274576000_4.1.e004266.15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21907"},{"key":"2025121411274576000_4.1.e004266.16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cam4.84","article-title":"Cancer survival disparities by health insurance status","volume":"2","author":"Niu","year":"2013","journal-title":"Cancer Med"},{"key":"2025121411274576000_4.1.e004266.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2013.05.058"},{"key":"2025121411274576000_4.1.e004266.18","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-008-0230-0"},{"key":"2025121411274576000_4.1.e004266.19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14694\/EdBook_AM.2013.33.271","article-title":"Disparities and challenges in adherence to oral antineoplastic agents","volume":"2013","author":"Accordino","year":"2013","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025121411274576000_4.1.e004266.20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22019"},{"key":"2025121411274576000_4.1.e004266.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"2025121411274576000_4.1.e004266.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"2025121411274576000_4.1.e004266.23","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-013-0234-8"},{"key":"2025121411274576000_4.1.e004266.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08010.x"},{"key":"2025121411274576000_4.1.e004266.25","unstructured":"Swerdlow SH Campo E Harris NL . WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer, 2008."},{"key":"2025121411274576000_4.1.e004266.26","unstructured":"Office for National Statistics, 2001 Census: Aggregate data (England and Wales) [computer file]. UK Data Service Census Support. Downloaded from: http:\/\/casweb.mimas.ac.uk."},{"key":"2025121411274576000_4.1.e004266.27","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.450"},{"key":"2025121411274576000_4.1.e004266.28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-271"},{"key":"2025121411274576000_4.1.e004266.29","unstructured":"Department of Health. Reducing cancer inequality: evidence, progress and making it happen: a report by the National Cancer Equality Initiative, 2010. www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_114353."},{"key":"2025121411274576000_4.1.e004266.30","unstructured":"Government D for C and L. English indices of deprivation 2010\u2014Publications\u2014GOV.UK. 2011. https:\/\/www.gov.uk\/government\/publications\/english-indices-of-deprivation-2010"},{"key":"2025121411274576000_4.1.e004266.31","unstructured":"Cancer Research UK Cancer Survival Group. strel computer program and life tables for cancer survival analysis. 2006. http:\/\/www.lshtm.ac.uk\/ncde\/cancersurvival\/tools.htm"},{"key":"2025121411274576000_4.1.e004266.32","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.38"},{"key":"2025121411274576000_4.1.e004266.33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324228"},{"key":"2025121411274576000_4.1.e004266.34","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23330"},{"key":"2025121411274576000_4.1.e004266.35","unstructured":"UK CR. Non-Hodgkin lymphoma diagnosis and treatment statistics. Cancer Research UK. http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/types\/nhl\/treatment\/diagnosis-and-treatment (accessed 26 Sep 2013)."},{"key":"2025121411274576000_4.1.e004266.36","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","article-title":"Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia","volume":"14","author":"Hoyle","year":"2011","journal-title":"Value Heal"},{"key":"2025121411274576000_4.1.e004266.37","unstructured":"Natonal Institute for Health and Clinical Excellence. Myelofibrosis (splenomegaly, symptoms)\u2014ruxolitinib: appraisal consultation document. NICE 2013. http:\/\/guidance.nice.org.uk\/TA\/Wave0\/615\/Consultation\/DraftGuidance (accessed 26 Sep 2013)."},{"key":"2025121411274576000_4.1.e004266.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495598"},{"key":"2025121411274576000_4.1.e004266.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.07.007"},{"key":"2025121411274576000_4.1.e004266.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.05.024"},{"key":"2025121411274576000_4.1.e004266.41","unstructured":"Oliver S Taylor F Bolton E . Haematological maligancies in England 2001\u20132008. 2012. http:\/\/www.ncin.org.uk\/cancer_type_and_topic_specific_work\/cancer_type_specific_work\/haematological_cancers\/"},{"key":"2025121411274576000_4.1.e004266.42","unstructured":"Natonal Institute for Health and Clinical Excellence. Leukaemia (chronic myeloid)\u2014imatinib. 2003. http:\/\/guidance.nice.org.uk\/TA70 (accessed 3 Oct 2013)."},{"key":"2025121411274576000_4.1.e004266.43","unstructured":"Natonal Institute for Health and Clinical Excellence. Leukaemia (chronic myeloid, first line)\u2014dasatinib, nilotinib and standard-dose imatinib. 2012. http:\/\/guidance.nice.org.uk\/TA251 (accessed 3 Oct 2013)."},{"key":"2025121411274576000_4.1.e004266.44","unstructured":"Natonal Institute for Health and Clinical Excellence. Leukaemia (chronic myeloid)\u2014dasatinib, nilotinib, imatinib (intolerant, resistant). 2012. http:\/\/guidance.nice.org.uk\/TA241 (accessed 3 Oct 2013)."},{"key":"2025121411274576000_4.1.e004266.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-423194"},{"key":"2025121411274576000_4.1.e004266.46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2147\/DDDT.S42902","article-title":"Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays","volume":"7","author":"Rezende","year":"2013","journal-title":"Drug Des Devel Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2013-004266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:27:53Z","timestamp":1765740473000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2013-004266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,15]]},"published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1136\/bmjopen-2013-004266"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2013-004266","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}